C07K 2318/20
Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region
Official title: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
C07K2318/20 (Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region) appears on 312 US grants and 624 published applications in this corpus.
Search patents in C07K- Granted patents
- 312
- Published applications
- 624
- Assignees
- 233
- Inventors
- 1,107
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 2 |
| 2003 | 0 | 4 |
| 2004 | 3 | 2 |
| 2005 | 1 | 6 |
| 2006 | 5 | 10 |
| 2007 | 4 | 6 |
| 2008 | 0 | 10 |
| 2009 | 1 | 14 |
| 2010 | 6 | 15 |
| 2011 | 2 | 11 |
| 2012 | 7 | 19 |
| 2013 | 11 | 24 |
| 2014 | 10 | 25 |
| 2015 | 14 | 27 |
| 2016 | 25 | 31 |
| 2017 | 25 | 45 |
| 2018 | 15 | 31 |
| 2019 | 26 | 38 |
| 2020 | 28 | 40 |
| 2021 | 30 | 56 |
| 2022 | 36 | 48 |
| 2023 | 16 | 36 |
| 2024 | 19 | 48 |
| 2025 | 18 | 42 |
| 2026 | 9 | 34 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-DR5 polypeptides and methods of use thereof1 Sep 2026US 12,723,094 B2Regents of the University of Minnesota
- Engineered binding proteins for recognition of bacteria11 Aug 2026US 12,704,514 B2Massachusetts Institute of Technology
- T-cell immunotherapy specific for WT-116 Jun 2026US 12,653,886 B2Fred Hutchinson Cancer Center
- Polypeptide improved in protein purity and affinity for antigen, conjugate thereof with antibody or antigen-binding fragment, and preparation method therefor12 May 2026US 12,624,099 B2Abclon Inc.
- T cell receptors and methods of use thereof28 Apr 2026US 12,611,450 B2University Health Network
- Stabilized fibronectin based scaffold molecules1 Oct 2026US 2026/0297811 A1Bristol-Myers Squibb Company
- Drug delivery systems24 Sep 2026US 2026/0284239 A1Antaros Tracer AB
- Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome24 Sep 2026US 2026/0285994 A1Viela Bio, Inc.
- Dual antigen-targeting protein complex comprising antibody or antigen- binding fragment thereof and affibody17 Sep 2026US 2026/0274966 A1Abclon Inc.
- Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome10 Sep 2026US 2026/0265388 A1Viela Bio, Inc.
Most cited
By later US patents
- Protein scaffolds for antibody mimics and other binding proteins232US 6,818,418 B1Compound Therapeutics, Inc. · 2004
- Artificial antibody polypeptides170US 6,703,199 B1Research Corporation Technologies, Inc. · 2004
- Artificial antibody polypeptides158US 6,673,901 B2Research Corporation Technologies, Inc. · 2004
- Protein scaffolds for antibody mimics and other binding proteins125US 7,115,396 B2Compound Therapeutics, Inc. · 2006
- Anticalins116US 7,250,297 B1Pieris AG · 2007